Low utility of blood culture in pediatric community-acquired pneumonia: An observational study on 2705 patients admitted to the emergency department

Jae Hyun Kwon, MD, MA\textsuperscript{a}, Jung Heon Kim, MD, MA\textsuperscript{b}, Jeong-Yong Lee, MD, MA\textsuperscript{b}, Youn-Jung Kim, MD, MA\textsuperscript{b}, Chang Hwan Sohn, MD, MA\textsuperscript{b}, Kyoung Soo Lim, MD, PhD\textsuperscript{b}, Won Young Kim, MD, PhD\textsuperscript{b}.*

Abstract
To investigate the utility of blood cultures performed on previously healthy children and adolescents with community-acquired pneumonia (CAP) at a tertiary care hospital emergency department (ED).

We reviewed 3235 patients with CAP aged 6 months to 18 years who underwent blood cultures at the ED from 2009 through 2016. CAP was defined according to the International Classification of Diseases, 10th Revision codes for pneumonia and the requirement of antibiotic treatment plus any of the following: radiologically confirmed, hospitalized, or moderate to severe disease. Blood cultures were retrospectively justified by the Infectious Diseases Society of America guidelines. We measured the yield (true positive results of blood culture) and impact (blood culture-directed change in the antibiotic regimen).

Of 2705 previously healthy patients with CAP, 833 (30.8%; 95% confidence interval [CI]: 29.1–32.6) underwent blood cultures justified by the current guidelines. We found 12 patients (0.4%; 95% CI: 0.2–0.8) having positive results of blood culture, 7 of whom underwent justifiable blood cultures. Of these 7 patients, 3 (0.11%; 95% CI: 0.02–0.3) had the yield, \textit{Streptococcus pneumoniae}. No impact was made in these 3 patients with \textit{S pneumoniae}.

We confirmed a low utility of blood cultures in previously healthy children and adolescents with CAP who were admitted to the ED. This finding suggests the need to refine the current guidelines for obtaining blood cultures in the ED for pediatric CAP.

Abbreviations: BC = blood culture, CAP = community-acquired pneumonia, ED = emergency department, PCV = pneumococcal conjugate vaccine.

Keywords: bacteremia, blood culture, pediatric emergency medicine, pneumococcal infections, pneumonia

1. Introduction
The Infectious Diseases Society of America recommends that blood culture (BC) should be limited to children and adolescents (hereafter designated as children, unless otherwise specified) with moderate to severe, presumed bacterial community-acquired pneumonia (CAP).\textsuperscript{1,2} The recent studies performed on hospitalized children with CAP show a prevalence of bacteremia, ranging from 1.1% to 7.0%\textsuperscript{,3–5} and a BC-directed change in the antibiotic regimen of 4.6%\textsuperscript{,4} However, the Infectious Diseases Society of America recommendation is based on low-quality evidence, and BC is still frequently performed on hospitalized children with CAP.\textsuperscript{5,6} The overuse of BC can lead to unnecessary venipuncture and antibiotic treatment.

In the emergency department (ED), BC is still frequently performed as an initial workup for CAP.\textsuperscript{7,8} A recent study performed on 238 children with CAP who underwent a BC at the ED shows 9 cases of bacteremia without any BC-directed change in the antibiotic regimen.\textsuperscript{9} Despite this, there is a lack of ED-based studies on the utility of BC in pediatric CAP with larger study populations.

In the ED, BC may not need to be performed on all children with moderate to severe CAP. We aimed to investigate the utility of BC in children with CAP who were admitted to the ED of a tertiary care hospital. We also compared the utility of BC in children with and without a BC justified by the current guidelines.

2. Methods
2.1. Study design and setting
This retrospective study was conducted at a tertiary care, university-affiliated hospital ED in Seoul, Korea, which has an annual census of approximately 40,000 children. We reviewed previously healthy children with CAP aged 6 months to 18 years...
as a primary diagnosis who were admitted to the ED and underwent a BC for the diagnosis of bacteremia from January 2009 through September 2016. At our institution, children with symptoms suggestive of CAP frequently undergo BC as part of an initial workup. During an epidemic, children undergo testing for viruses or Mycoplasma pneumoniae. Children aged <6 months were excluded since they were partially immunized with pneumococcal conjugate vaccine (PCV) and were likely to benefit from BC given their susceptibility to bacteremia. In Korea, 10- and 13-valent PCV (PCV10/13) were licensed in 2010, and were included in the national immunization program in 2014. It is speculated that at least 65% and 40% of the children underwent the immunization and recent antibiotic treatment, respectively.[10,11] The study protocol was approved by the institutional review board with a waiver for informed consent (IRB No. 2016-1204).

2.2. Definitions and exclusion criteria
To investigate the utility of BC, we measured the yield and impact. The yield was defined as the presence of a single pathogenic bacterium from the blood, excluding contaminants. The impact was defined as a BC-directed change in the antibiotic regimen. CAP was defined according to the International Statistical Classification of Diseases and Related Health Problems, 10th Revision codes for pneumonia (J10–J18) and the requirement of antibiotic treatment, implying the presumed bacterial CAP, plus any of the following: consolidation, peribronchial infiltration or pleural effusion on a chest radiograph; hospitalization; or moderate to severe disease according to the current guidelines.[1]

We excluded the children for any of the following: known cardiopulmonary diseases; presumed viral or noninfectious pneumonia; nonambulatory status (e.g., cerebral palsy); known immunocompromised status; indwelling devices (e.g., tracheostomy tube); and healthcare-associated pneumonia, which was confirmed >48h after ED presentation or <2 weeks after discharge from a hospital.

2.3. Performance, justification, and interpretation of BC
BC was performed using BACTEC FX (Becton, Dickinson and Company, Franklin Lakes, NJ). During the study period, it was a routine procedure that an attending physician or nurse aseptically draws a sample of blood, and inoculates the sample into a pair of aerobic and anaerobic bottles (≥1 mL for each bottle). BC was retrospectively justified if it had been performed on children with respiratory distress (as defined in Section 2.5), admission to the intensive care unit or a complicated pneumonia.[1] Pathogenic bacteria were defined as one of the following: Streptococcus pneumoniae, Staphylococcus aureus, group A beta-hemolytic streptococci, and Haemophilus influenzae. Contaminants were defined as one of the following: coagulase-negative staphylococci, viridans group streptococci, Bacillus spp., Micrococcus spp., Propionibacterium spp., and Corynebacterium spp. If no growth was reported after 5 days of BC, it was considered negative.

2.4. Testing for viruses or M pneumoniae
Viral or atypical etiology should be mentioned in pediatric CAP since these etiologies are more common than bacteria. We used a virus real-time polymerase chain reaction using CFX96 (BIORAD, Hercules, CA) and an influenza antigen test using Sofia Fluorescent Immunoassay Analyzer (Quidel, San Diego, CA) from the nasopharyngeal secretion. A M pneumoniae IgM chemiluminescence immunoassay was performed using LIASON M pneumoniae IgM (DiaSorin S.p.A., Saluggia, Italy) from the blood.

2.5. Data collection
We used standardized data collection sheets. Clinical characteristics including age, gender, body temperature, signs of respiratory distress (age-adjusted tachypnea, chest retraction, and oxyhemoglobin saturation <90%), and outcome (admission to general wards or intensive care units, transfer, and death) were obtained. Age-adjusted tachypnea was defined as a respiratory rate >50/min in children aged 6 to 12 months, >40/min in those aged 1 to 5 years, and >20/min in those aged >5 years.[1] Concentrations of inflammatory biomarkers including white blood cell, absolute neutrophil count, and C-reactive protein were recorded. For children with multiple visits, information on the earliest visit was used.

2.6. Statistical analysis
For comparison of clinical characteristics between the children with and without justified BC, Student t tests or Mann–Whitney U tests were used for continuous variables, and chi-squared tests or Fisher exact tests for categorical variables. A P of <.05 was considered statistically significant. Statistical analysis was performed using SPSS for Windows version 21.0 (SPSS Inc, Chicago, IL).

3. Results
3.1. Study population
From a total of 3235 children with CAP who underwent BC at the ED during the study period, 2705 met all inclusion criteria (Fig. 1). Table 1 outlines the clinical characteristics. Overall, BC was justified in 833 children (justified BC group: 30.8%; 95% confidence interval [CI]: 29.1–32.6). These children had older age and higher frequency of male gender. They also had higher frequencies of admission and M pneumoniae, and higher concentration of C-reactive protein. BC was justified mainly by the respiratory distress (89.4%). Among the children with...
Table 1
Clinical characteristics of the study population.

| Characteristics          | Total (n=2705) | BC justified (n=1872) | BC unjustified (n=833) | P |
|--------------------------|---------------|-----------------------|------------------------|---|
| Age, y                   | 2.0 (1.0–5.0) | 5.0 (2.0–7.0)         | 2.0 (1.0–4.0)          | <.001 |
| Male gender              | 1419 (52.5)   | 469 (50.3)            | 950 (50.7)            | .01 |
| Temp, °C                 | 38.1 ± 1.0    | 38.0 ± 1.0            | 38.1 ± 1.0            | .02 |
| Respiratory distress     | 747 (27.5)    | 745 (89.4)            | NA                    | NA |
| Admission, total         | 597 (22.1)    | 305 (36.6)            | 292 (15.6)            | <.001 |
| Intensive care unit      | 35 (1.3)      | 35 (4.2)              | NA                    | NA |
| Transfer                 | 43 (1.6)      | 17 (2.0)              | 26 (1.4)              | <.001 |
| Chest radiograph         | Infiltrates   | 2289 (84.6)           | 729 (87.5)            | .01 |
|                          | Complications | 133 (4.9)             | 133 (16.0)            | NA |
|                          | WBC, 10^3/μL  | 9.0 (6.8–13.0)        | 8.7 (6.5–12.6)        | 9.3 (6.9–13.2) | <.001 |
|                          | ANC, 10^3/μL  | 5.0 (3.3–7.7)         | 5.2 (3.5–7.9)         | 5.0 (3.2–7.6) | .02 |
|                          | CRP, mg/dL    | 2.6 (1.2–4.7)         | 3.2 (1.3–5.5)         | 2.4 (1.1–4.4) | .001 |
|                          | Positive BC   | 12 (4.1)              | 7 (0.8)               | 5 (0.3)       | .06 |
|                          | Viruses†      | 710 (62.7)            | 263 (60.2)            | 447 (64.3) | .16 |
|                          | MP‡           | 1044 (49.0)           | 399 (60.2)            | 445 (65.7) | <.001 |

Values are expressed as mean ± standard deviation, median (interquartile range), or n (%).

ANC = absolute neutrophil count, BC = blood culture, CRP = C-reactive protein, MP = Mycoplasma pneumoniae, NA = not applicable, WBC = white blood cell.

‡ Assessed by the Infectious Diseases Society of America guidelines.[1]

† Plasma C-reactive protein (CRP) was not measured in 109 (10.1%) children.

‡ Plasma C-reactive protein (CRP) was not measured in 109 (10.1%) children.

3.2. Yield and impact

Of 2705 children, 12 (0.4%; 95% CI: 0.2–0.8) had positive results of BC (Table 2). Of these, only 3 children (0.11%; 95% CI: 0.02–0.3) had the yield, S pneumoniae, and 2 of whom had this bacterium from BCs performed at referring hospitals without additional yield following referral to the ED. No impact was found in these 3 children. The other 9 children were considered to have contaminants (overall contamination rate: 0.3%; 95% CI: 0.2–0.6). Hence, in our cohort, the prevalence of bacteremia was 0.11% without any BC-directed change in the antibiotic regimen. The girl aged 3 years with the yield (patient 1, Table 2) had CAP manifested as consolidation and pleural effusion. Subsequently, she underwent antibiotic treatment and drainage of the pleural effusion, which was proven sterile on culture. After 27 days of admission in the general ward, she was discharged without complications. Two boys with the yield from referring hospitals (patients 2 and 3, Table 2) had similar hospital courses, except that patient 3 had atelectasis as a sequel. All 3 children had CAP from 2010 through 2012 before PCV10/13 were included in the Korean national immunization program.

Of 2 children who had positive results of BC among the 530 excluded children, 1 with known ventricular septal defect had a yield, methicillin-resistant S aureus, without an impact. This child had been presumed as having transient bacteremia, and recovered without antibiotic treatment.

3.3. Viruses and M pneumoniae

One thousand one hundred thirty-two (41.8%) and 2131 (78.8%) children, primarily hospitalized, underwent testing for viruses and M pneumoniae, respectively (Table 1). We were unable to have a complete dataset with these etiologies. M pneumoniae was the single, most common pathogen in this study (38.6%, 1044 of the 2705 children). Among the viruses detected, rhinovirus was most common, followed by respiratory syncytial virus (see Table, Supplemental Digital Content, which shows the viral etiology, http://links.lww.com/MD/B713). Overall, 64.8% (1467 of the 2263 children who underwent testing for viruses or M pneumoniae) had a coinfection of viruses or M pneumoniae, and this coinfection was more frequent in the justified BC group (70.9%, 537 of the 757 children vs. 61.8%, 930 of the 1506 children, P < .001).

4. Discussion

We found a low utility of BC for the diagnosis of bacteremia in a highly selected population, consisting of previously healthy children aged 6 months to 18 years with CAP who were admitted to the ED of a tertiary care hospital. To the best of our knowledge, this study used the largest ED-based study popula-
tion for studies on this topic. The prevalence of bacteremia (0.11%) indicates that the number needed to test was approximately 909. Judicious use of BC can decrease unnecessary venipuncture and antibiotic treatment.

Our yield was lower than the prevalence of bacteremic CAP in the post-PCV10/13 era, ranging from 1.1% to 1.5%. This discrepancy was likely due to the exclusion of underlying medical conditions, along with the lower probability of selection bias in our cohort. The age of the children with bacteremia (2–3 years) corroborates the previous reports. Older age and higher frequency of severe disease) are parallel to the characteristics of critically ill children. The older age and gender predominance were comparable to a population-based study in the United States. Older age and male predominance in the justiﬁed BC group (i.e., moderate to severe disease) are parallel to the characteristics of critically ill children. The younger age in the unjustiﬁed BC group agrees with a study showing that younger children with CAP undergo BC more frequently.

The low yield suggests the need to reﬁne the current guidelines for obtaining BC in the ED, with an emphasis on the risk factors of bacteremia rather than disease severity itself. The justiﬁed BC group still had low yield, suggesting that moderate to severe disease does not necessarily mean the potential of bacteremia. The justiﬁed BC group showed a higher frequency of conﬁrmation of virus infection in this group can be partially explained, as this bacterium is more prevalent in children aged >5 years. The younger age in the unjustiﬁed BC group agrees with a study showing that younger children with CAP undergo BC more frequently.

Several limitations related to the single center, retrospective design are worth mentioning. It is unknown whether there was a high suspicion of bacterial CAP at presentation. Some cases of viral CAP or bronchiolitis might be logically excluded by the deﬁnition of CAP used in this study. Still, the proportion of children having viruses (26.2%) implies some degree of misclassiﬁcation. Although BC was justiﬁed according to the current guidelines, some criteria such as the Pediatric Early Warning Score were unable to be assessed. The single-centered setting possibly mitigates the strength of the largest ED-based study population. However, this matter might be less important given the probably low selection bias compared to previous studies.

In summary, we found a low utility of BC in previously healthy children with CAP at the ED. This study encourages the reﬁnement of the current guidelines for obtaining BC from children with CAP in the ED. Future studies may focus on determining the risk factors of bacteremia in previously healthy children with CAP and the utility of polymerase chain reaction for the diagnosis of S pneumoniae bacteremia.

Acknowledgment

The authors appreciate the statistical consultation of Minju Kim, a statistician.

References

[1] Bradley JS, Rivington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011;53: e25–76.
[2] Sandora TJ, Desai R, Miko BA, et al. Assessing quality indicators for pediatric community-acquired pneumonia. Am J Med Qual 2009;24: 419–27.
[3] Grant CC, Harniden A, Munt D, et al. Why do children hospitalised with pneumonia not receive antibiotics in primary care? Arch Dis Child 2012;97:21–7.
[4] Myers AL, Hall M, Williams DJ, et al. Prevalence of bacteremia in hospitalized pediatric patients with community-acquired pneumonia. Pediatr Infect Dis J 2013;32:736–40.
[5] Davis TR, Evans HR, Murtas J, et al. Utility of blood cultures in children admitted to hospital with community-acquired pneumonia. J Paediatr Child Health 2017;53:232–6.
[6] McCulloh RJ, Koster MP, Yin DE, et al. Evaluating the use of blood cultures in the management of children hospitalized for community-acquired pneumonia. PLoS ONE 2015;10:e0117462.
[7] Shah SS, Dugan MH, Bell LM, et al. Blood cultures in the emergency department evaluation of childhood pneumonia. Pediatr Infect Dis J 2011;30:475–9.
[8] Florin TA, French B, Zorc JJ, et al. Variation in emergency department diagnostic testing and disposition outcomes in pneumonia. Pediatrics 2013;132:237–44.
[9] Astete JA, Batlle A, Hernandez-Bou S, et al. Blood culture diagnostic yield in a paediatric emergency department. Eur J Emerg Med 2014;21:336–40.
[10] Choe YJ, Yang JJ, Park SK, et al. Comparative estimation of coverage between national immunization program vaccines and non-NIP vaccines in Korea. J Korean Med Sci 2013;28:1283–8.
[11] HIRAAS. Wonju (Korea): Health Insurance Review and Assessment Service; 2007. HIRA report: appropriateness of health insurance coverage for medication; the first half of 2013. Available from: http://www.hira.or.kr/co/search.do?searchWord=%EC%95%BD%EC%A0%9C%EA%B8%89%EC%97%AC%EC%A0%81%EC%A0%95%EC%84%B1+%ED%88%98%EA%B0%80 [Korean]. Accessed January 31, 2017.
[12] Iroh-Yam PY, Bernstein E, Ma X, et al. Blood culture in evaluation of pediatric community-acquired pneumonia: a systematic review and meta-analysis. Hosp Pediatr 2015;3:324–36.
[13] Heine D, Cochran C, Moore M, et al. The prevalence of bacteremia in pediatric patients with community-acquired pneumonia: guidelines to reduce the frequency of obtaining blood cultures. Hosp Pediatr 2013;3:92–6.
[14] Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med 2015;372:835–45.
[15] Woods-Hill CZ, Faucett J, Nelson McMillan K, et al. Association of a clinical practice guideline with blood culture use in critically ill children. JAMA Pediatr 2017;171:157–64.
[16] Koh JW, Wong JJ, Sultana R, et al. Risk factors for mortality in children with pneumonia admitted to the pediatric intensive care unit. Pediatr Pulmonol 2017; doi: 10.1002/ppul.23702. [Epub ahead of print].
[17] Parkik H, Davis AB, Pavuluri P. Do we need this blood culture? Hosp Pediatr 2014;4:73–84.
[18] Lee H, Choi EH, Lee HJ. Effects of antibiotic treatment for children with pneumonia admitted to the pediatric intensive care unit. Pediatr Pulmonol 2017; doi: 10.1002/ppul.23702. [Epub ahead of print].
[19] Parikh K, Davis AB, Pavuluri P. Do we need this blood culture? Hosp Pediatr 2014;4:73–84.
[20] Lee H, Choi EH, Lee HJ. Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines. Korean J Pediatr 2014;57:55–66.
[21] Kim JW, Seo HK, Yoo EG, et al. Mycoplasma pneumoniae pneumonia in Korean children, from 1979 to 2006—a meta-analysis. Korean J Pediatr 2009;52:315–23.
[22] Gadbury NJ, Reynolds AJ, McNemarin J, et al. Increased reports of Mycoplasma pneumoniae from laboratories in Scotland in 2010 and 2011—impact of the epidemic in infants. Euro Surveill. 2012;17 pii:20110.